Literature DB >> 26376702

Rare presentation of orbital plasmablastic lymphoma with oral cavity involvement in an HIV-negative patient.

Sidhertha Podder1, Prerna Khetan2, Shetra Sivamurthy3, Kaushik Mandal4.   

Abstract

Plasmablastic lymphoma is described as a subtype of non-Hodgkin's lymphoma under the category of diffuse large B-cell lymphoma. It is classified by WHO as HIV-associated lymphoma of the oral cavity. Several cases have been reported in non-HIV patients with extra-oral involvement. The characteristic immunohistochemical markers are generally positive for CD138, CD38 and MUM1/IRF4, and negative or weakly positive for pan B-cell markersCD20, CD79a, PAX-5 and BCL-6. We report a rare case of orbital plasmablastic lymphoma with oral and oropharyngeal involvement where the immunohistochemical markers were positive for CD138, CD43, CD45, CD79a and MUM1. A small subset of markers was weakly positive for CD20, CD30 and κ, and negative for CD10, BCL-6, CD4, CD56 and Epstein-Barr virus-encoded small RNA (EBER). Our case reinforces the fact that plasmablastic lymphoma is a different entity of non-Hodgkin's lymphoma that cannot simply be classified under diffuse large B-cell lymphoma. It demands modification of the WHO classification. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26376702      PMCID: PMC4577708          DOI: 10.1136/bcr-2015-211960

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  8 in total

Review 1.  Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations.

Authors:  C M Flaitz; C M Nichols; D M Walling; M J Hicks
Journal:  Oral Oncol       Date:  2002-01       Impact factor: 5.337

2.  Extra-oral plasmablastic lymphoma: report of a case and review of literature.

Authors:  Fabio Tavora; Luis F Gonzalez-Cuyar; Chen-Chih J Sun; Allen Burke; X Frank Zhao
Journal:  Hum Pathol       Date:  2006-07-07       Impact factor: 3.466

3.  Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy.

Authors:  Sunita D Nasta; George M Carrum; Imran Shahab; Nicola A Hanania; Mark M Udden
Journal:  Leuk Lymphoma       Date:  2002-02

4.  Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection.

Authors:  H J Delecluse; I Anagnostopoulos; F Dallenbach; M Hummel; T Marafioti; U Schneider; D Huhn; A Schmidt-Westhausen; P A Reichart; U Gross; H Stein
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

Review 5.  Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature.

Authors:  Mark A Scheper; Nikolaos G Nikitakis; Rui Fernandes; Christopher D Gocke; Robert A Ord; John J Sauk
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2005-08

6.  Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.

Authors:  Francisco Vega; Chung-Che Chang; Leonard J Medeiros; Mark M Udden; Jeong Hee Cho-Vega; Ching-Ching Lau; Chris J Finch; Regis A Vilchez; David McGregor; Jeffrey L Jorgensen
Journal:  Mod Pathol       Date:  2005-06       Impact factor: 7.842

7.  Human immunodeficiency virus-negative plasmablastic lymphoma in Korea.

Authors:  Ji Eun Kim; Young A Kim; Wook Youn Kim; Chul Woo Kim; Young Hye Ko; Geon Kook Lee; Suk-Jin Choi; Yoon Kyung Jeon
Journal:  Leuk Lymphoma       Date:  2009-04

8.  Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities.

Authors:  Lluís Colomo; Florence Loong; Susana Rives; Stefania Pittaluga; Antonio Martínez; Armando López-Guillermo; Jesús Ojanguren; Vicens Romagosa; Elaine S Jaffe; Elías Campo
Journal:  Am J Surg Pathol       Date:  2004-06       Impact factor: 6.394

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.